BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dawnzera (Donidalorsen) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dawnzera (Donidalorsen)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05392114-10797@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT05392114)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in
  the Prophylactic Treatment of Hereditary Angioedema (HAE)\nEstimated prim
 ary completion: December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05392114
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07298447-10797@assetmemo.bio
DTSTAMP:20261121T005617Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Dawnzera (Donidalorsen): Phase 3 readout est. (NCT07298447)
DESCRIPTION:Dawnzera (Donidalorsen)\, phase 3\, Hereditary Angioedema.\nStu
 dy: Donidalorsen Treatment in Children With Hereditary Angioedema\nEstimat
 ed primary completion: June 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/donidalorsen#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07298447
URL:https://assetmemo.bio/drug/donidalorsen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
